Financial & competing interests disclosure
Nicholas W Morrell has received a research grant from Novartis and has provided consultancy for Actelion and Novartis. Lewis J Rubin is a member of the Scientific Board of United Therapeutics and is a consultant for Actelion, Bayer-Schering, Pfizer, GeNo, Aires, Gilead and GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.